Ammerbuch, Germany

Stefan Odenbreit

This inventor holds 3 USPTO granted patents. Top assignees: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. , Other. Active years: 2000-2003.


% Patents Active = 100.0

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Munchen, DE (2000)
  • München, DE (2002)
  • Ammerbuch, DE (2003)

Company Filing History:


Years Active: 2000-2003

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Stefan Odenbreit

Introduction

Stefan Odenbreit is a notable inventor based in Ammerbuch, Germany. He has made significant contributions to the field of biotechnology, particularly in the study of Helicobacter pylori. With a total of 3 patents to his name, Odenbreit has focused on understanding the genetic mechanisms of this bacterium and its implications for human health.

Latest Patents

Odenbreit's latest patents include groundbreaking work on an adherence gene from Helicobacter pylori. This invention concerns a polypeptide coded by the gene and antibodies against the polypeptide. Another significant patent is a process for identifying secretory genes from Helicobacter pylori, which outlines a method for identifying adherence genes and includes a suitable gene bank for this purpose.

Career Highlights

Throughout his career, Odenbreit has been associated with the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. This prestigious institution has provided a platform for his research and innovations in the field of microbiology and genetics.

Collaborations

Some of Odenbreit's notable coworkers include Thomas F. Meyer and Rainer Haas. Their collaborative efforts have contributed to advancing the understanding of Helicobacter pylori and its genetic components.

Conclusion

Stefan Odenbreit is a distinguished inventor whose work has significantly impacted the field of biotechnology. His patents reflect a deep understanding of genetic mechanisms and their applications in health science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…